Excipient Market Overview: Roquette announces restructuring post IFF Pharma buyout; WHO, FDA advance regulatory frameworks

Data Compilation
#PharmaFlow

Pipeline Prospector May 2025: Pfizer strikes US$ 6 bn oncology pact; Lilly diversifies pipeline with US$ 2.3 bn in deals

Stock Recap
#PipelineProspector

Propafenone, HCl

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

22 API Suppliers, 12 USDMF, 5 CEP/COS, 2 JDMF, 3 EU WC, 2 KDMF, 14 NDC API, 7 Listed Suppliers, $ API Reference Price

INTERMEDIATES

1 Intermediate Suppliers

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

103 FDF Dossiers, 53 FDA Orange Book, 30 Europe, 10 Canada, 2 South Africa, 8 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 150MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 225MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, EXTENDED RELEASE;ORAL - 225MG, CAPSULE, EXTENDED RELEASE;ORAL - 325MG, CAPSULE, EXTENDED RELEASE;ORAL - 425MG

RELATED EXCIPIENT COMPANIES

5 SPI Pharma, 10 DKSH, 6 Faran Shimi Pharmaceutical, 8 Boai NKY Pharmaceuticals Ltd, 5 Gangwal Healthcare, 4 Nanjing Well Pharmaceutical, 4 ACG Worldwide, 6 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 Ashland, 32 BASF, 11 Corel Pharma Chem, 7 DFE Pharma, 2 Finar, 11 Gangwal Chemicals, 5 Ideal Cures Pvt Ltd, 4 Ingredion Pharma Solutions, 37 Kerry, 4 Kima Chemical, 6 Lonza Capsugel, 15 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nomisma Healthcare, 3 Novo Excipients, 4 Pharmatrans-Sanaq, 6 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 25 Roquette, 14 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 11 Sigachi Industries, 4 Silverline Chemicals, 3 The Dow Chemical Company, 2 Ulanqab Kema New Material, 1 Valens Pharmachem, 4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

79 Fillers, Diluents & Binders, 51 Coating Systems & Additives, 39 Disintegrants & Superdisintegrants, 32 Granulation, 31 Direct Compression, 31 Controlled & Modified Release, 30 Thickeners and Stabilizers, 29 Solubilizers, 19 Lubricants & Glidants, 19 Co-Processed Excipients, 17 Film Formers & Plasticizers, 15 Topical, 13 Taste Masking, 10 Parenteral, 9 Emulsifying Agents, 9 Chewable & Orodispersible Aids, 9 Empty Capsules, 6 API Stability Enhancers, 6 Rheology Modifiers, 5 Coloring Agents, 4 Vegetarian Capsules, 3 Surfactant & Foaming Agents

DIGITAL CONTENT

14 News #PharmaBuzz

14 News #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 33 Regulatory FDF Prices

MARKET PLACE

7 APIs, 3 FDF Dossiers

REF. STANDARDS & IMPURITIES

2 EDQM, 1 USP

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Name of the Firm	Written Confirmation No.	Product Name	Issue Date	Valid Till	Address of the Firm
04/06/2025	PharmaZell	Germany	M/s Pharmazell India Private Limited	WC-0102n	Propafenone Hydrochloride USP	2022-06-24	2025-07-02	Plot No. B5&B6, A1&A2, MEPZ-Tambaram, Chennai-600 045, India
04/06/2025	Tianish Laboratories	India	M/s Tianish Laboratories Privte Lmited	WC-0117	Propafenone Hydrochloride Ph. Eur.	2022-06-22	2025-07-28	Plot No. 14, 99, 100, IDA, Pashmylaram, Phase ? II, Patancheru, Sangareddy District 502 307, Telangana State, India

Propafenone, HCl

Propafenone, HCl

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

22 API Suppliers

12 USDMF

5 CEP/COS

2 JDMF

3 EU WC

2 KDMF

14 NDC API

7 Listed Suppliers

$ API Reference Price

INTERMEDIATES

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

103 FDF Dossiers

53 FDA Orange Book

30 Europe

10 Canada

2 South Africa

8 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 150MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 225MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE, EXTENDED RELEASE;ORAL - 225MG

CAPSULE, EXTENDED RELEASE;ORAL - 325MG

CAPSULE, EXTENDED RELEASE;ORAL - 425MG

RELATED EXCIPIENT COMPANIES

5 SPI Pharma

10 DKSH

6 Faran Shimi Pharmaceutical

8 Boai NKY Pharmaceuticals Ltd

5 Gangwal Healthcare

4 Nanjing Well Pharmaceutical

4 ACG Worldwide

6 Actylis

1 Aeon Procare

1 Alcedo Pharmachem

9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

2 Ashland

32 BASF

11 Corel Pharma Chem

7 DFE Pharma

2 Finar

11 Gangwal Chemicals

5 Ideal Cures Pvt Ltd

4 Ingredion Pharma Solutions

37 Kerry

4 Kima Chemical

6 Lonza Capsugel

15 Microlex e.U

1 Nanjing Bold Chemical

2 Nomisma Healthcare

3 Novo Excipients

4 Pharmatrans-Sanaq

6 Pluviaendo

4 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

2 Qualicaps

25 Roquette

14 Seppic

6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

11 Sigachi Industries

4 Silverline Chemicals

3 The Dow Chemical Company

2 Ulanqab Kema New Material

1 Valens Pharmachem

4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

79 Fillers, Diluents & Binders

51 Coating Systems & Additives

39 Disintegrants & Superdisintegrants

32 Granulation

31 Direct Compression

TABLET;ORAL - 150MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 225MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 300MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons